Skip to content
Clinical Trials – home
Therapeutic area

Cardiac disorders – page 34

  • 481 clinical trials
  • 225 recruiting
  • 172 conditions
  • 28 countries

Conditions in this area

172 conditions with trials, the busiest first

Clinical trials in Cardiac disorders

481 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

481 clinical trials

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Novartis Pharma AG

Cardiogenic shock

Not recruiting

Study on the Effects of Levosimendan for Patients with Cardiogenic Shock Being Weaned from ECMO

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken

Cardiac failure+1

Not recruiting

Study on Vericiguat for Children with Heart Failure from Left Ventricular Systolic Dysfunction

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety of CRD-4730 for Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Crd-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Atrial fibrillation+1

Not recruiting

Study on Rivaroxaban for Patients with Atrial Fibrillation and Coronary Artery Disease After Heart Procedure

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Amsterdam UMC Stichting

Study on the Effects of MYK-224 for Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bms-986435
  • Sponsor:Myokardia Inc.

Cardiac failure

Not recruiting

Study on Empagliflozin's Effect on Heart Function in Non-Diabetic Pre-Heart Failure Patients Using Fitbit and mHealth for Exercise Guidance

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:University College Dublin

Angina pectoris

Not recruiting

Study on the Effect of Diltiazem on Angina in Patients with Coronary Microvascular Dysfunction

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cellulose, Microcrystalline
  • Sponsor:Stichting Radboud University Medical Center

Cardiovascular disorder+1

Not recruiting

Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lerodalcibep
  • Sponsor:Lib Therapeutics LLC
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alxn2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on the Safety and Tolerability of BMS-986435 in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bms-986435
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Cardiac disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.